Expanded Access Protocol (EAP) For Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Lunning, Matthew
Contact Information:
Sarah Snook
sarah.snook@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT04400591?term=NCT04400591&rank=1
Summary
The primary objective of the study is to assess the safety of nonconforming lisocabtagene maraleucel in patients.
The secondary objective of the study is to assess the efficacy of nonconforming lisocabtagene maraleucel in patients.
Exploratory objectives of the study are to assess duration of response (DOR), progression-free survival (PFS), and overall survival (OS).